Ainuovirine

Ainuovirine
Clinical data
Other namesACC-007, KM-023, Aibangde, Einovirine
Identifiers
  • 3-(3-ethyl-2,6-dioxo-5-propan-2-ylpyrimidine-4-carbonyl)-5-methylbenzonitrile
CAS Number
PubChem CID
ChemSpider
ChEMBL
PDB ligand
Chemical and physical data
FormulaC18H19N3O3
Molar mass325.368 g·mol−1
3D model (JSmol)
  • CCN1C(=C(C(=O)NC1=O)C(C)C)C(=O)C2=CC(=CC(=C2)C#N)C
  • InChI=InChI=1S/C18H19N3O3/c1-5-21-15(14(10(2)3)17(23)20-18(21)24)16(22)13-7-11(4)6-12(8-13)9-19/h6-8,10H,5H2,1-4H3,(H,20,23,24)
  • Key:AYPIJAMXGVYYRQ-UHFFFAOYSA-N

Ainuovirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Kainos Medicine for the treatment of HIV infections.[1] Ainuovirine was approved in China in 2021 for the treatment of HIV-1 infection.[2]

References

  1. ^ "Ainuovirine - Kainos Medicine". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Zhang Q, Chen Z, Wang Y, Peng Y, Tan S, Li Y, et al. (2023). "Impacts of ainuovirine-based and efavirenz-based antiretroviral therapies on the lipid profile of HIV/AIDS patients in southern China: a real-world study". Frontiers in Medicine. 10 1277059. doi:10.3389/fmed.2023.1277059. PMC 10800701. PMID 38259850.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.